Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed relapsed or refractory HIV-associated non-Hodgkin lymphoma (NHL)

  * Must have histologic or cytologic documentation of prior AIDS-associated NHL (i.e., at time of diagnosis) for clinically relapsed and/or refractory disease for which biopsy is not feasible
  * Must have documented HIV seropositivity
  * Must have documentation of Epstein-Barr Virus (EBV)- and/or human herpes virus-8 (HHV-8)- positive infection within the lymphoma (i.e., LMP-1, LANA expression, or positive Epstein-Barr-encoded RNAs \[EBERs\])

PATIENT CHARACTERISTICS:

Inclusion criteria:

* ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%
* Life expectancy \> 2 months
* ANC ≥ 1,000/mm³\* (growth factor support allowed)
* Hemoglobin ≥ 8.0 g/dL\* (growth factor support allowed)
* Platelet count ≥ 100,000/mm³
* Total bilirubin ≤ 1.5 mg/dL
* AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN)
* Serum creatinine ≤ ULN
* Creatinine clearance ≥ 50 mL/min
* Negative pregnancy test
* Not pregnant or nursing
* Fertile patients must use effective contraception NOTE: \*Patients with lymphomatous involvement of the bone unable to meet hematologic criteria are allowed

Exclusion criteria:

* Peripheral neuropathy ≥ grade 2
* Uncontrolled intercurrent illness including, but not limited to, any of the following:

  * Ongoing or active infection

    * Opportunistic infections controlled by antimicrobial or suppressive therapy allowed, unless the investigator judges the infection likely to become life-threatening in the setting of multi-agent chemotherapy
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * NYHA class III or IV heat failure
  * Myocardial infarction within the past 6 months
  * Uncontrolled angina
  * Severe uncontrolled ventricular or other cardiac arrhythmias
  * Acute ischemia or active conduction system abnormalities by ECG
  * Serious psychiatric or medical illness, that would interfere with study compliance
* Social situations that would interfere with study compliance
* Acute active HIV-associated opportunistic infection requiring antibiotic treatment

  * Mycobacterium avium or candidiasis allowed unless concurrent therapy with moderate-to-strong CYP3A4 inducers or inhibitors is required
  * Chronic myelosuppressive agent therapy allowed provided hematologic criteria are met
* Hypersensitivity to compounds of similar chemical or biological composition to bortezomib, boron, mannitol, ifosfamide, carboplatin, or etoposide
* Concurrent malignancy except carcinoma in situ of the cervix, in situ anal cancer, nonmetastatic nonmelanoma skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy
* Active hepatitis B infection (hepatitis B surface antigen-positive), unless 1 of the following criteria are met:

  * Able to start dual anti-hepatitis B adefovir and telbivudine therapy prior to study
  * Receiving dual anti-hepatitis B therapy for at least 12 weeks prior to study with either agent active against HIV (i.e., entecavir, tenofovir, lamivudine, or emtricitabine)
* Concurrent grapefruit juice/fruit or green tea

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Recovered from prior adverse effects due to agents administered more than 3 weeks earlier
* Glucocorticoid therapy within the past 3 weeks allowed
* More than 3 weeks since prior chemotherapy
* More than 2 weeks since prior radiotherapy
* More than 14 days since prior and no other concurrent investigational agents (other than bortezomib)
* No concurrent moderate-to-strong CYP3A4 inducers or inhibitors other than protease inhibitors
* Concurrent stable (at least 12 weeks) antiretroviral regimen allowed